



Biomarker Testing in Gastric & Gastroesophageal Cancers

Clinical Brief #4

References

Battaglin F, Naseem M, Puccini A, Lenz HJ. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. *Cancer Cell Int.* 2018;18(1):99. doi:10.1186/s12935-018-0594-z

ClinicalTrials.gov. A study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (GLOW). NCT03653507. Updated March 17, 2022. Accessed March 31, 2022. <https://clinicaltrials.gov/ct2/show/NCT03653507>

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet.* 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2

JEMPERLI (dostarlimab-gxly) [prescribing information]. GlaxoSmithKline. Approved 2021. Revised April 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Esophageal and Esophagogastric Cancers (v2.2022). Updated February 11, 2022. Accessed March 30, 2022. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric Cancer (v2.2022). Updated January 11, 2021. Accessed March 30, 2022. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. *Br J Surg.* 2018;105(3):159-167. doi:10.1002/bjs.10663

ROZLYTREK (entrectinib) [prescribing information]. Genentech. Approved 2019. Revised November 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212725s005lbl.pdf

VITRAKVI® (larotrectinib) [prescribing information]. Bayer HealthCare Pharmaceuticals Inc. Approved 2018. Revised March 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210861s006lbl.pdf

Glossary

1L, first line

2L, second line

CLDN18.2, claudin-18 isoform 2

CPS, combined positive score

FGFR2b, fibroblast growth factor receptor 2 isoform IIIb

FISH, fluorescence in situ hybridization

G, gastric

GEJ, gastroesophageal junction

GI, gastrointestinal

HER2, human epidermal growth factor receptor 2

IHC, immunohistochemistry

ISH, in situ hybridization

MMR, mismatch repair

MSI, microsatellite instability

NGS, next-generation sequencing

NTRK, neurotrophic tyrosine receptor kinase

PCR, polymerase chain reaction

PD-L1, programmed death-ligand 1

T-DXd, trastuzumab deruxtecan